Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Dexamethasone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The name of your medicine is Dexamethasone Tablets (called dexamethasone throughout this leaflet). Dexamethasone is a synthetic glucocorticoid (adrenocortical hormone) with an effect on metabolism, electrolyte balance and tissue functions. Dexamethasone is used for: Neurology Swelling of the brain caused by brain tumours, neurosurgery, bacterial inflammation of the lining of the brain (meningitis), brain abscess. Pulmonary and respiratory diseases Severe acute asthma attack
Dermatology Initial treatment of extensive acute severe skin diseases, such as erythroderma, pemphigus vulgaris or acute eczema. Autoimmune disorders/rheumatology Treatment of rheumatic systemic diseases (rheumatic diseases that can affect internal organs), such as systemic lupus erythematosus. Severely progressive form of active rheumatic joint inflammation (rheumatoid arthritis), e.g. forms that quickly lead to joint destruction and/or when tissue outside the joints is affected. Infectology Severe infectious diseases with intoxication-like conditions (like tuberculosis, typhoid fever), only in addition to appropriate anti-infective therapy. Oncology Supportive treatment for malignant tumours. COVID-19 Treatment of coronavirus disease 2019 (COVID-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) with difficulty breathing and need of oxygen therapy. Endocrinology Hormone replacement therapy: in reduced or failure of adrenal function (adrenogenital syndrome) in adulthood. Various
e Dexamethasone Do not take dexamethasone
Talk to your doctor before taking dexamethasone if you have or are suspected of having pheochromocytoma (a tumour of the adrenal glands). Treatment with glucocorticoids can lead to underactive adrenal cortex (insufficient endogenous production of glucocorticoids), depending on the dose and duration of treatment, this can last for several months and in individual cases longer than a year after discontinuation of treatment. If you experience particular physical stress (such as illnesses with fever, accidents or surgery, childbirth, etc.) during treatment with glucocorticoids, you should tell your doctor or inform the emergency doctor about your ongoing treatment. A temporary increase in the daily dose of dexamethasone may be required. Even in case of continued underactive adrenal cortex after the end of treatment, the administration of glucocorticoids may be necessary in physical stress situations. Therefore, during long-term treatment with dexamethasone, your doctor should give you a steroid card, which you should always carry with you. In order to avoid treatment-induced acute adrenal insufficiency, when treatment discontinuation is intended, your doctor will determine a dose-reduction plan, which you should follow. By suppressing the body's immune system, treatment with dexamethasone can lead to an increased risk of bacterial, viral, parasitic, opportunistic and fungal infections. It can mask the signs and symptoms of an existing or a developing infection, making it more difficult to recognize them. Latent infections can be reactivated. In the following illnesses, treatment with dexamethasone tablets should only be started if your doctor considers it essential. If necessary, medications that act against the pathogens should also be taken:
The risk of tendon pain, tendon inflammation and tendon rupture is increased when fluoroquinolones (certain antibiotics) and dexamethasone are administered together. During the treatment of a particular form of muscle paralysis (myasthenia gravis), symptoms may worsen at the beginning. Vaccinations Vaccinations with vaccines from killed pathogens (inactivated vaccines) are generally possible. However, it should be noted that the immune response and thus vaccine may be compromised at higher doses of corticoids. Long-term treatment
Symptoms of tumour lysis syndrome, such as muscle cramping, muscle weakness, confusion, visual loss or disturbances and shortness of breath, in case you suffer from haematological malignancy. Contact your doctor if you experience blurred vision or other visual disturbances. Treatment with this medicine may cause pheochromocytoma crisis, which can be fatal. Pheochromocytoma is a rare tumour of the adrenal glands. Crisis can occur with the following symptoms: headaches, sweating, palpitations, and hypertension. Contact your doctor immediately if you experience any of these signs. Children and adolescents Due to the risk of growth inhibition, dexamethasone should only be administered in children for compelling medical reasons, and during long-term treatment growth in height should be controlled regularly. Therapy with dexamethasone tablets should be of limited duration or it should be carried out alternatingly (e.g. every other day, but then double dose). Dexamethasone should not be used routinely in preterm neonates with respiratory problems. Elderly In elderly patients, a special risk-benefit analysis should be carried out because of the increased risk of osteoporosis. Effects in case of misuse for doping purposes The use of dexamethasone can lead to positive results in doping controls. Other medicines and dexamethasone Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. What other medicines influence the effect of dexamethasone?
side effects, such as confusion, hallucinations, dizziness, tiredness, sleepiness, fainting or blurred vision. Dexamethasone contains lactose and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Dexamethasone Always take this medicine exactly as your doctor has told you. Your doctor will determine the dose for you individually. Please follow the instructions in order for dexamethasone tablets to have the proper effect. Check with your doctor or your pharmacist if you are not sure. Unless otherwise prescribed by your doctor, the usual doses for the following conditions are:
If you stop taking dexamethasone Always follow the dosing schedule prescribed by the doctor. Dexamethasone tablets must never be discontinued without discussion with your doctor, particularly since long-term treatment can lead to a decrease in the body's production of glucocorticoids (underactive adrenal cortex). This is a highly physically stressful situation without adequate glucocorticoid production and can be fatal. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. In hormone replacement therapy, the risk of side effects is low with the use of recommended doses. With prolonged use, especially of high doses, however, side effects of varying degrees can be expected regularly, but their frequency cannot be clearly specified. Infections and infestations Masking of infections, occurrence, recurrence and worsening of viral, fungal, bacterial infections and parasitic or opportunistic infections, activation of threadworm infection. Blood and lymphatic system disorders Blood count changes (increase in white blood cells or all blood cells, decrease in certain white blood cells). Immune system disorders Hypersensitivity reactions (e.g. drug eruption), severe anaphylactic reactions, such as cardiac arrhythmia, bronchospasm (spasm of bronchial smooth muscle), high or low blood pressure, circulatory collapse, cardiac arrest (heart stops pumping blood), weakening of the immune system. Endocrine disorders Cushing's syndrome (typical signs include moon face, central obesity and facial flushing), hypofunction or atrophy of the adrenal cortex. Metabolism and nutrition disorders Weight gain, elevated blood sugar levels, diabetes, increase in blood lipids (cholesterol and triglycerides), increased sodium levels with swelling (oedema), potassium deficiency due to increased potassium excretion (may lead to heart arrhythmias), increased appetite.
Psychiatric disorders Depression, irritability, euphoria, increased drive, psychoses, mania, hallucinations, mood swings, anxiety, sleep disorders, suicidal tendencies. Nervous system disorders Increased intracranial pressure, occurrence of a previously unrecognized epilepsy, more frequent occurrence of seizures (fits) in already known epilepsy. Eye disorders Increase in intraocular pressure (glaucoma), clouding of the lens (cataract), worsening of corneal ulcers, increased occurrence or worsening of eye inflammation caused by viruses, bacteria or fungi, worsening of bacterial inflammations of the cornea, drooping eyelid, pupil dilation, conjunctival swelling, perforation of the white of the eye, visual disturbances, loss of vision and blurred vision. Vascular disorders High blood pressure, increased risk of arteriosclerosis and thrombosis, inflammation of blood vessels (also as a withdrawal syndrome after long-term treatment) and increased fragility of blood vessels. Gastrointestinal disorders Gastrointestinal ulcers, gastrointestinal bleeding, inflammation of pancreas, stomach discomfort, hiccups. Skin and subcutaneous tissue disorders Stretch marks on the skin, thinning of the skin ("parchment skin"), enlargement of skin blood vessels, tendency to bruising, skin bleeding in dots or patches, increased body hair, acne, inflammatory skin changes on the face, especially around the mouth, nose and eyes, changes in skin pigmentation. Musculoskeletal and connective tissue disorders Muscle disorders, muscle weakness and wasting, bone loss (osteoporosis) are dose-related and possible even with only short-term use, other forms of bone death (osteonecrosis), tendon disorders, tendonitis, tendon ruptures, fat deposits in the spine (epidural lipomatosis), growth inhibition in children. Note: Too rapid dose reduction after long-term treatment may cause a withdrawal syndrome with symptoms such as muscle and joint pain. Reproductive system and breast disorders Disorders of sex hormone secretion (consequently: irregular or absent menstruation (amenorrhea), male-like body hair in women (hirsutism), impotence).
General disorders and administration site conditions Delayed wound healing Measures Please talk to your doctor or pharmacist if you notice any of the listed side effects or other unwanted effects during treatment with dexamethasone tablets. Never stop treatment on your own. If gastrointestinal discomfort, pain in the back, shoulder or hip area, psychological disorders, abnormal blood sugar fluctuations (in diabetics) or other disturbances occur, please inform your doctor immediately. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the MHRA Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For COVID-19 products/treatments report side effects directly via Yellow Card Scheme website: https://coronavirusyellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
dexamethasone Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'. The expiry date refers to the last day of that month. Store below 25oC. Store in original package in order to protect from light. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Dexamethasone tablets look like and contents of the pack Dexamethasone 0.5 mg tablets: White to off white, round, flat bevelled edge tablet approximately 8 mm in diameter, engraved with DX on one side and 500 on the other side. Dexamethasone 1 mg tablets: White to off white, round, flat bevelled edge tablet approximately 8 mm in diameter, engraved with DX on one side and 1 on the other side. Dexamethasone 2 mg tablets: White to off white, round, flat bevelled edge tablet approximately 8 mm in diameter, engraved with DX on one side and 2 on the other side. Packed into Alu/PVC/PVDC blisters. Pack sizes: 10, 20, 30, 50 or 100 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder Zentiva Pharma UK Limited 12 New Fetter Lane London EC4A 1JP United Kingdom Manufacturer(s): Custom Pharmaceuticals Ltd Conway Street, Hove BN3 3LW United Kingdom This leaflet was last revised in September 2023.
What Dexamethasone tablets contain:
1065039065
Dexamethasone 1mg tablets comes as tablet containing 1mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Dexamethasone 1mg tablets is dexamethasone.
This leaflet reproduces the patient information leaflet approved for Dexamethasone 1mg tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Neurology
Cerebral oedema caused by brain tumours, neurosurgery, bacterial meningitis, brain abscesses.
Pulmonary and respiratory diseases
Severe acute asthma attacks.
Dermatology
Oral initial treatment of extensive, acute, severe skin diseases that respond to glucocorticoids, such as erythroderma, pemphigus vulgaris or acute eczema.
Autoimmune disorders/rheumatology
Oral initial treatment of autoimmune diseases, such as systemic lupus erythematosus (especially visceral forms). Severe progressive form of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations.
Infectology
Severe infectious diseases with toxic-like conditions (e.g. tuberculosis, typhoid fever) only with concomitant anti-infective therapy.
Oncology
Palliative treatment of malignant tumours.
Endocrinology
Congenital adrenogenital syndrome in adulthood.
COVID-19
The treatment of coronavirus disease 2019 (COVID-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy.
Various
Prophylaxis and treatment of emesis induced by cytostatics, emetogenic chemotherapy within antiemetic treatment.
Prevention and treatment of postoperative vomiting, with in antiemetic treatment .
Posology
Dosage depends on the type and severity of the disease and the individual patient's response to the therapy. In general, relatively high initial doses are used, which must be significantly higher in acute severe courses than in chronic diseases.
Unless otherwise prescribed, the following dosage recommendations apply:
• Cerebral oedema
Depending on cause and severity, initial dose of 8 - 10 mg (up to 80 mg) i.v., followed by 16 - 24 mg (up to 48 mg)/day orally, divided into 3 - 4 (up to 6) single doses over 4 - 8 days. A longer term, lower-dose administration of Dexamethasone tablets may be necessary during radiotherapy and in the conservative therapy of inoperable brain tumours.
• Cerebral oedema due to bacterial meningitis
0.15 mg/kg bodyweight, every 6 hours for 4 days.
Children: 0.4 mg/kg body weight every 12 hours for 2 days, starting before the first antibiotic administration.
• Severe acute asthma attacks
Adults: 8 - 20 mg, then if required, 8 mg every 4 hours.
Children: 0.15 - 0.3 mg/kg bodyweight.
• Acute skin conditions
Depending on the type and extent of the disease, daily doses of 8-40 mg. Followed by treatment with decreasing doses.
• Active phases of systemic rheumatic diseases
Systemic lupus erythematosus: 6 – 16 mg daily.
• Severely progressive form of Active rheumatoid arthritis
In rapidly destructive forms 12-16mg/day, in extra-articular manifestations:
6 - 12 mg/day.
• Severe infectious diseases, toxic conditions (e.g. tuberculosis, typhoid fever)
4 - 20 mg/day for a few days, only with concomitant anti‑infective therapy.
• Palliative treatment of malignant tumours
Initially 8 - 16 mg/day, for prolonged treatment 4 - 12 mg/day.
• Congenital adrenogenital syndrome in adulthood
0.25 - 0.75 mg/day, taken as a single dose. If necessary, additional administration of a mineralocorticoid (fludrocortisone). In the case of special physical stress (e.g. trauma, surgery), intercurrent infections, etc., a 2- to 3- fold increase may be required and under extreme stress (e.g. childbirth) a 10- fold increase.
• For the treatment of Covid-19
Adult patients: 6 mg, intravenously or orally, once a day for up to 10 days.
Paediatric population: Paediatric patients (adolescents aged 12 years and older) are recommended to take 6 mg/dose, intravenously or orally, once a day for up to 10 days.
The duration of treatment should be guided by the clinical response and the individual patient requirements.
Elderly, renal impairment, hepatic impairment: No dose adjustment is needed.
• Prophylaxis and therapy of cytostatic-induced vomiting in the context of antiemetic treatment plans: 0 - 20 mg before starting chemotherapy, then 4 - 8 mg up to 2 to 3 times a day for 1 - 3 days (moderately emetogenic chemotherapy) or up to 6 days (highly emetogenic chemotherapy) if necessary.
• Prophylaxis and treatment of postoperative vomiting
Single dose of 8-20 mg before the start of surgery
Children from 2 years of age and older: 0.15-0.5 mg/kg bodyweight (max. 16 mg).
Method of administration
The tablets should be swallowed whole after a meal and taken with plenty of liquid. The daily dose should be administered as a single dose in the morning if possible (circadian therapy). In patients who require high-dose therapy because of their disease, multiple daily doses are often required to achieve maximum effect.
Depending on the underlying disease, clinical symptoms and response to therapy, the dose can be reduced at a faster or slower rate and the therapy stopped, or the patient is stabilised on a maintenance dose as low as possible and, if necessary, adrenal axis monitored. Basically, the dose and duration of treatment should be kept as high and long as necessary, but as low and short as possible. In principle, the dose should be reduced gradually.
In long-term therapy which is deemed necessary following initial treatment, patients should be switched to prednisone/prednisolone, because this leads to lower adrenal suppression.
In hypothyroidism or liver cirrhosis, low doses may be sufficient or a dose reduction may be necessary.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Depending on the dose and duration of therapy, adrenalcortical insufficiency caused by glucocorticoid therapy may continue for several months and in individual cases more than a year after cessation of therapy. In cases of particular physical stress situations (trauma, surgery, childbirth, etc.) during treatment with Dexamethasone tablets, a temporary increase in dose may be required. Because of the potential risk in stress situations, patients on extended therapy should be issued a steroid card. Also in prolonged adrenal insufficiency after cessation of treatment, the administration of glucocorticoids may be necessary in physical stress situations. In case of intended withdrawal, treatment-induced acute adrenal insufficiency may be minimized by slow dose reduction.
Infections and vaccinations
Through immunosuppression, treatment with Dexamethasone can lead to an increased risk of bacterial, viral, parasitic, opportunistic and fungal infections. It can mask the symptoms of an existing or developing infection, thereby making a diagnosis more difficult. Latent infections, like tuberculosis or hepatitis B, can be reactivated.
Treatment with Dexamethasone tablets should only be implemented in the event of the strongest indications and if necessary, additional targeted anti-infective therapy administered in the following illnesses:
• acute viral infections (Herpes zoster, Herpes simplex, Varicella, Herpes keratitis)
• HBsAg-positive chronic active hepatitis
• approximately 8 weeks before, or up to 2 weeks after, vaccination with live vaccines;
• systemic mycosis and parasitosis (e.g. nematodes)
• in patients with suspected or confirmed strongyloidiasis (infection with thread worms, as glucocorticoids may lead to activation and mass proliferation of these parasites
• poliomyelitis
• lymphadenitis following BCG vaccination
• acute and chronic bacterial infections
• if there is a history of tuberculosis (reactivation risk), use only under tuberculostatic drugs protection.
In addition, therapy with dexamethasone should only be implemented under strong indications and, if necessary, additional specific treatment must be implemented in the following conditions:
• gastrointestinal ulcers
• osteoporosis
• severe cardiac insufficiency
• high blood pressure that is difficult to regulate
• diabetes mellitus that is difficult to regulate
• psychiatric disorders (including in the past), including suicidality: neurological or psychiatric monitoring is recommended.
• narrow- and wide-angle glaucoma: ophthalmic monitoring and adjunctive therapy are recommended.
• corneal ulcerations and corneal injuries: ophthalmic monitoring and adjunctive therapy are recommended.
In COVID-19 infection, systemic corticosteroids should not be stopped for patients who are already treated with systemic (oral) corticosteroids for other reasons (e.g. patients with chronic obstructive pulmonary disease) but not requiring supplemental oxygen.
Gastrointestinal disease
Because of the risk of intestinal perforation, Dexamethasone tablets should only be used where there are compelling reasons to do so and under appropriate monitoring in:
• severe ulcerative colitis with an imminent perforation, this may occur without peritoneal irritation
• diverticulitis
• enteroanastomosis (immediately after surgery).
The signs of peritoneal irritation following gastrointestinal perforation may be absent in patients receiving high doses of glucocorticoids.
Diabetes
The possibility of a higher need for insulin or oral antidiabetics must be taken into consideration when administering Dexamethasone tablets to diabetics.
Other conditions:
Regular blood pressure monitoring is necessary during treatment with Dexamethasone tablets, particularly during administration of higher doses and in patients with high blood pressure that is difficult to regulate.
Because of the risk of deterioration, patients with severe cardiac insufficiency should be carefully monitored.
With high doses of dexamethasone bradycardia may occur.
Severe anaphylactic reactions may occur.
The risk of tendon disorders, tendinitis and tendon rupture is increased when fluoroquinolones and glucocorticoids are administered together.
A concurrent myasthenia gravis may initially worsen during treatment with Dexamethasone tablets.
Vaccination with inactivated vaccines are possible. However, it should be noted that the immune response and thus the response to the vaccine may be compromised at higher doses of corticosteroids.
During long-term therapy with Dexamethasone tablets, regular medical checks (including ophthalmologic every three months) are indicated.
At high doses, sufficient calcium intake and sodium restriction should be ensured and serum potassium levels should be monitored.
Depending on the dose and duration of treatment, a negative effect on calcium metabolism can be expected; therefore, the prevention of osteoporosis is recommended. This applies especially to patients with concomitant risk factors, such as familial predisposition, advanced age, postmenopausal period, insufficient protein and calcium intake, heavy smoking, excessive alcohol consumption and lack of physical activity. Prevention consists of sufficient calcium and vitamin D intake and physical activity. In already existing osteoporosis, additional drug therapy should be considered.
Upon termination of long-term administration of glucocorticoids, the following risks must be
taken into account:
• exacerbation or relapse of the underlying disease,
• acute adrenal insufficiency,
• cortisone withdrawal syndrome.
Certain viral diseases (chickenpox, measles) may be very severe in patients treated with glucocorticoids. Immunocompromised patients without previous chickenpox or measles infection are particularly at risk. If these patients have contact with people infected with measles or chickenpox while undergoing treatment with Dexamethasone tablets, a preventative treatment should be introduced, if necessary.
In post-marketing experience tumour lysis syndrome (TLS) has been reported in patients with haematological malignancies following the use of dexamethasone alone or in combination with other chemotherapeutic agents. Patient at high risk of TLS, such as patients with high proliferative rate, high tumour burden, and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precaution taken.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Pheochromocytoma crisis
Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.
Paediatric population
In the growth phase of children, the risk-benefit ratio of treatment with Dexamethasone tablets should be carefully weighed.
Therapy should be of limited duration or in case of long-term therapy, it should be carried out alternatingly.
Preterm neonates
Available evidence suggests long-term neuro-developmental adverse events, after early treatment (< 96 hours after birth) of premature infants with chronic lung disease at starting doses of 0.25 mg/kg twice daily.
Elderly population:
Because elderly patients are at increased risk of osteoporosis, the benefit-risk ratio of treatment with Dexamethasone tablets should be carefully weighed.
Note:
The use of Dexamethasone tablets can lead to positive results in doping controls.
Excipients with known effect
This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Estrogens (e.g. oral contraceptives)
The half-life of glucocorticoids may be prolonged. Therefore the effect of the corticoids may be increased.
Antacids
Concomitant administration of aluminium or magnesium hydroxide may lead to a reduction in the absorption of glucocorticoids with reduced efficacy of Dexamethasone tablets. There should be a 2-hour interval between the intake of one and the other drug.
Medicines inducing CYP3A4, such as rifampicin, phenytoin, carbamazepine, barbiturates and primidone
The effect of corticoids can be reduced.
CYP3A inhibitors (including ketoconazole, itraconazole, ritonavir and cobicistat)
Co-treatment with CYP3 inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
Drugs that inhibit CYP3A4, such as ketoconazole and itraconazole: The effect of corticoids may be increased.
Ephedrine
The metabolism of glucocorticoids may be accelerated, thereby reducing their effectiveness.
ACE-inhibitors
Increased risk of blood count changes.
Cardiac glycosides
The effect of glycosides may be increased by potassium deficiency.
Saluretics/laxatives
Potassium excretion may be increased.
Antidiabetic agents
The hypoglycaemic effect may be reduced.
Coumarin derivatives
The anticoagulant effect may be reduced or increased. Dosage adjustment of the anticoagulant may be necessary when co-administered.
Non-steroidal anti-inflammatory/antirheumatic drugs (NSARs), salicylates and indomethacin
The risk of gastrointestinal ulceration and bleeding is increased.
Non-depolarising muscle relaxants
The muscle-relaxing effect may last longer.
Atropine, other anticholinergics
Additional intraocular pressure increases are possible with concomitant use.
Praziquantel
Corticosteroids may cause a reduction of the praziquantel concentration in the blood.
Chloroquine, hydroxychloroquine, mefloquine
There is an increased risk of myopathy and cardiomyopathy.
Somatropin
The effects of somatropin can be reduced during long-term therapy.
Protirelin
Reduced increase in TSH may be noted during administration of protirelin.
Immunosuppressive agents
Increased susceptibility to infections and possible aggravation or manifestation of latent infections. Additionally, for ciclosporin: The blood levels of ciclosporin are increased, so there is an increased risk of seizures.
Fluoroquinolones
Fluoroquinolones may increase the risk of tendon disorders.
Influence on investigative methods
Skin reactions in allergy tests can be suppressed.
Pregnancy
The ability of corticosteroids to cross the placenta varies between individual drugs, however, dexamethasone readily crosses the placenta.
Administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate, intra-uterine growth retardation and effects on brain growth and development. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate/lip in man (see also section 5.3). However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation. Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to corticosteroids but usually resolves spontaneously following birth and is rarely clinically important. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks. When corticosteroids are essential however, patients with normal pregnancies may be treated as though they were in the non-gravid state.
Breast-feeding
Corticosteroids may pass into breast milk, although no data are available for dexamethasone. Infants of mothers taking high doses of systemic corticosteroids for prolonged periods may have a degree of adrenal suppression.
A decision on whether to continue/discontinue breast feeding or to continue/discontinue therapy with dexamethasone should be made taking into account the benefit of breast feeding to the child and the benefit of dexamethasone therapy to the woman.
Fertility
Dexamethasone decreases testosterone biosynthesis and endogenous ACTH secretion which has an effect on the spermatogenesis and the ovarian cycle.
No studies have been conducted on the effects on the ability to drive or to operate machinery.
Hormone replacement therapy
Low risk of side effects if recommended dosages are followed.
Pharmacotherapy
The following side effects may occur, which depend very much on the dose and duration of therapy and whose frequency cannot therefore be stated.
Infections and infestations
Masking of infections, manifestation and exacerbation of viral infections, fungal infections, bacterial, parasitic and opportunistic infections, activation of strongyloidiasis.
Blood and lymphatic system disorders
Moderate leukocytosis, lymphocytopenia, eosinopenia, polycythemia.
Immune system disorders
Hypersensitivity reactions (e.g. drug eruption), severe anaphylactic reactions, such as arrhythmias, bronchospasm, hypo- or hypertension, circulatory collapse, cardiac arrest, weakening of the immune system.
Endocrine disorders
Adrenal suppression and induction of Cushing's syndrome (typical symptoms: moon face, central obesity and plethora).
Metabolism and nutrition disorders
Sodium retention with oedema, increased potassium excretion (risk of arrhythmias), weight gain, reduced glucose tolerance, diabetes mellitus, hypercholesterolemia and hypertriglyceridemia, increased appetite.
Psychiatric disorders
Depression, irritability, euphoria, increased drive, psychoses, mania, hallucinations, emotional lability, anxiety, sleep disorders, suicidality.
Nervous system disorders
Pseudotumor cerebri, manifestation of latent epilepsy, increase in seizure susceptibility in manifest epilepsy.
Eye disorders
Cataract, especially with posterior subcapsular opacity, glaucoma, deterioration of symptoms associated with corneal ulcer, increased occurrence of viral, fungal and bacterial inflammation of the eye, deterioration of bacterial inflammation of the cornea, ptosis, mydriasis, chemosis, iatrogenic scleral perforation, chorioretinopathy, vision, blurred (see also section 4.4).
Vascular disorders
Hypertension, increased risk of atherosclerosis and thrombosis, vasculitis (also as withdrawal syndrome after long-term therapy), increased capillary fragility.
Gastrointestinal disorders
Gastrointestinal ulcers, gastrointestinal bleeding, pancreatitis, stomach discomfort, hiccups.
Skin and subcutaneous tissue disorders
Striae rubra, atrophy, telangiectasias, petechiae, ecchymosis, hypertrichosis, steroid acne, rosacea-like (perioral) dermatitis, changes in skin pigmentation.
Musculoskeletal and connective tissue disorders
Myopathy, muscle atrophy and weakness, osteoporosis (dose-dependent, possible also in short-term administration), aseptic bone necrosis, tendon disorders, tendinitis, tendon rupture, epidural lipomatosis, growth inhibition in children.
Note:
Too rapid dose reduction after long-term treatment may cause symptoms such as muscle and joint pain.
Reproductive system and breast disorders
Disorders of sexual hormone secretion (consequently: irregular menstruation up to amenorrhea, hirsutism, impotence).
General disorders and administration site conditions
Delayed wound healing.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Acute intoxications with dexamethasone are not known. In case of chronic overdosing, an increase in undesirable effects, especially endocrine, metabolic and electrolyte-related effects, can be expected (see section 4.8).
Management
There is no known antidote to dexamethasone.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Dexamethasone 1mg tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.